Association of body mass index with mortality and postoperative survival in renal cell cancer patients, a meta-analysis
Metrics: PDF 1069 views | HTML 2113 views | ?
Jiao Zhang1,2,*, Qiang Chen2,*, Zhan-Ming Li1, Xu-Dong Xu1, Ai-Fang Song1 and Li-Shun Wang1,2
1Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, ShanghaI 201199, China
2School of Public Health Taishan Medical University, Taian, Shandong 271000, China
*These authors contributed equally to this work
Li-Shun Wang, email: [email protected]
Ai-Fang Song, email: [email protected]
Keywords: renal cell cancer; BMI; postoperative survival; mortality; meta-analysis
Received: May 12, 2017 Accepted: December 05, 2017 Published: January 12, 2018
Obesity is one of the major risk factors of cancer. However, how body mass index (BMI) influences the prognosis of renal cell cancer (RCC) patient is unclear. In this work, we have performed a meta-analysis to elucidate the role of abnormal weight in RCC mortality and postoperative survival. Articles related to BMI and RCC mortality as well as postoperative survival has been identified by searching PUBMED and ENBASE. Totally, 19 articles have been selected for this meta-analysis, 5 articles for RCC mortality and 14 for postoperative survival. Compared to normal weight, the estimated relative risks of RCC mortality are 0.71 (95% CI: 0.34–1.49), 1.19 (95% CI: 1.05–1.35) and 1.71 (95% CI: 1.27–2.00) respectively for the underweight, overweight and obesity patients. The risk of RCC mortality increase 5% for each 1 kg/m² increment of BMI. However, the estimated hazard ratios of cancer specific postoperative survival are 2.62 (95% CI: 1.67–4.11), 0.72 (95% CI: 0.63–0.83) and 0.66 (95% CI: 0.49–0.89) respectively for underweight, overweight and obesity RCC patients. The risk of hazard ratio decrease 5% for each 1 kg/m² increment of BMI. In addition, the hazard ratios of postoperative overall survival show a similar tendency. These results indicate an opposite association of BMI with mortality and postoperative survival in renal cell cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.